← Compound Library

Vapreotide

Somatostatin Analog

Also known as: RC-160

A synthetic somatostatin analog studied for variceal bleeding & carcinoid syndrome. Available in some European countries.

Typical Dose

25 mcg bolus then 25 mcg/h IV infusion (variceal bleeding)

Route

Intravenous infusion or SubQ

Cycle

Acute (5 days for variceal bleeding)

Half-life

~1–2 hours

Storage

Per manufacturer.

ⓘ

Insights on this page are consolidated from peer-reviewed literature and aggregated research data. They do not constitute medical advice. Consult a qualified healthcare professional before use.

Overview

Vapreotide is a synthetic somatostatin analog used in some countries for acute variceal bleeding (splanchnic vasoconstriction) & carcinoid syndrome. Less widely used than octreotide; limited to specific indications in selected markets.

Research Indications

Acute variceal bleeding

Effective

Reduces portal pressure via splanchnic vasoconstriction. Similar to octreotide for acute use.

Side Effects & Safety

Common

  • Nausea
  • Hyperglycemia
  • Bradycardia

Uncommon

  • Hypoglycemia

When to Stop

  • Signs of allergic reaction
  • Significant bradycardia

How to Reconstitute

1

Commercial product for clinical use.

Dosing math: Clinical use only.

Quality Indicators

Good — use as normal

  • Per manufacturer

Discard immediately

  • Per manufacturer

What to Expect

First 5 days

Variceal bleeding control.

Community Insights

Self-reported. Reflects user experience, not clinical outcomes.

Verify what you have

Information on this page applies to pharmaceutical-grade peptides. Purity & identity of research-grade products vary. Certipep provides independent ESI-QTOF-MS & HPLC analysis with a signed analytical report.

Submit a sample